Menu Search
Equities

EvokAI Creative Labs Inc

OKAIF:QBB

EvokAI Creative Labs Inc

Actions
  • Price (USD)0.10
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 21 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EvokAI Creative Labs Inc. is a MedTech artificial-intelligence-powered company. It is engaged in the development of transformational technologies for the modern health care sector. It deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions, and provide more accurate diagnoses. It offers its AI algorithms across the whole health care system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations to medical professionals, patients, and healthy individuals, aiming at preventing and early detecting any kind of disease and protecting the aging genome. Its divisions include EvokAI Simulators, EvokAI Sensors, EvokAI Neurotrainer and EvokAI Medical. EvokAI Simulators combines cognitive neuroscience, virtual reality and artificial intelligence technologies to assess cognitive performance and spatial perception.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-17.08m
  • Incorporated2017
  • Employees--
  • Location
    EvokAI Creative Labs Inc1600-609 Granville StreetPacific CentrePO Box 10068VANCOUVER V7Y 1C3CanadaCAN
  • Phone+1 (778) 331-8505
  • Fax+1 (778) 508-9923
  • Websitehttps://www.evokailabs.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.